NRAS and acute myeloid leukemia: Similarly, in AML-99, we observed the selection of subclones with NRAS mutation along with the acquisition of PTPN11, FLT3-ITD, and IDH1 mutations during treatment with azacitidine and enasidenib (an IDH2 inhibitor).